Access Update – #02
William Prescott uttered those famous words to his troops in the Battle of Bunker Hill during the Revolutionary War. Prescott understood the importance of patience and waiting until the perfect time to act.
For those of you who have just read our report on Electro-Optical Sciences (Nasdaq: MELA), please remember Prescott’s words. We have a buy rating on MELA up to $5.75. The name of the game is buy low, sell high.
The shares have been volatile lately on the heels of our recommendation, as well as new coverage by a Wall Street firm last week. Nothing has changed fundamentally for the company. We expect there will be plenty of opportunity for you to get into the stock at more favorable prices in the coming weeks. Sit tight and wait for the stock to come to you at your price.
But stay alert and be prepared to take action. These small-cap stocks can move in a hurry. As soon as there is news, or even rumors, in the marketplace, we’ll be on top of it, guiding you every step of the way. We believe this stock will be at least a ten bagger by the time we’re through with it, but there will likely be opportunities along the way to add more and take profits. So it’s important to pay attention to each update that we send you.
And don’t forget our conference call with the CEO, CFO and melanoma specialist, Dr. Gary Peck, which will take place on Monday, April 7, at 3:30 p.m. ET.
Access subscribers can participate in the call by dialing 800.214.0694 or 719.955.1425. Use passcode 222419. Please email your questions for the executives or myself to research@accessresearchgroup.com .
Thanks again for subscribing to Access. And by the way, we’re close to wrapping up our research on an exciting stem cell company that will not face political controversy as the cells are taken from the patient, not embryos. The company already has products available in several countries and could be approved in the United States in the next year.
Even better, the shares have been beaten up lately. If that scenario holds we’ll have an opportunity to get in on the cheap. Stay tuned.
Marc Lichtenfeld
Director of Research
Access Research Group